scholarly journals Lin28 and HER2: Two stem cell regulators conspire to drive aggressive breast cancer

Cell Cycle ◽  
2012 ◽  
Vol 11 (15) ◽  
pp. 2780-2781 ◽  
Author(s):  
Fayaz Malik ◽  
Hasan Korkaya ◽  
Shawn G. Clouthier ◽  
Max S. Wicha
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Aggressive Breast Cancer

Abstract 3876: Can Nanog activity identify aggressive breast cancer stem cell populations

2014 ◽  
Author(s):  
Thomas J. Sayers ◽  
Rachel de Kluyver ◽  
Marcella Kaddoura ◽  
Jim Stauffer ◽  
Poonam Tewary ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Breast Cancer Stem Cell ◽  
Cell Populations ◽  
Stem Cell Populations ◽  
Aggressive Breast Cancer

Ovatodiolide sensitizes aggressive breast cancer cells to doxorubicin, eliminates their cancer stem cell-like phenotype, and reduces doxorubicin-associated toxicity

2015 ◽  
Vol 364 (2) ◽  
pp. 125-134 ◽  
Author(s):  
Oluwaseun Adebayo Bamodu ◽  
Wen-Chien Huang ◽  
David T.W. Tzeng ◽  
Alexander Wu ◽  
Liang Shun Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Cancer Stem Cell ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Aggressive Breast Cancer

scholarly journals The Stem Cell Phenotype of Aggressive Breast Cancer Cells

Cancers ◽  
2019 ◽  
Vol 11 (3) ◽  
pp. 340 ◽  
Author(s):  
Naira Margaryan ◽  
Hannah Hazard-Jenkins ◽  
Mohamad Salkeni ◽  
Matthew Smolkin ◽  
James Coad ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Drug Resistance ◽  
Stem Cell ◽  
Cancer Cells ◽  
Standard Of Care ◽  
Cell Phenotype ◽  
New Findings ◽  
Aggressive Breast Cancer ◽  
Stem Cell Phenotype ◽  
Heterogeneous Tumor

Aggressive cancer cells are characterized by their capacity to proliferate indefinitely and to propagate a heterogeneous tumor comprised of subpopulations with varying degrees of metastatic propensity and drug resistance properties. Particularly daunting is the challenge we face in the field of oncology of effectively targeting heterogeneous tumor cells expressing a variety of markers, especially those associated with a stem cell phenotype. This dilemma is especially relevant in breast cancer, where therapy is based on traditional classification schemes, including histological criteria, differentiation status, and classical receptor markers. However, not all patients respond in a similar manner to standard-of-care therapy, thereby necessitating the need to identify and evaluate novel biomarkers associated with the difficult-to-target stem cell phenotype and drug resistance. Findings related to the convergence of embryonic and tumorigenic signaling pathways have identified the embryonic morphogen Nodal as a promising new oncofetal target that is reactivated only in aggressive cancers, but not in normal tissues. The work presented in this paper confirms previous studies demonstrating the importance of Nodal as a cancer stem cell molecule associated with aggressive breast cancer, and advances the field by providing new findings showing that Nodal is not targeted by standard-of-care therapy in breast cancer patients. Most noteworthy is the linkage found between Nodal expression and the drug resistance marker ATP-binding cassette member 1 (ABCA1), which may provide new insights into developing combinatorial approaches to overcome drug resistance and disease recurrence.

High-dose chemotherapy and hematopoietic stem cell transplantation for breast cancer: Past or future?

2001 ◽  
Vol 28 (4) ◽  
pp. 377-388 ◽  
Author(s):  
Roy D. Baynes ◽  
Roger D. Dansey ◽  
Jared L. Klein ◽  
Caroline Hamm ◽  
Mark Campbell ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Stem Cell ◽  
Hematopoietic Stem Cell Transplantation ◽  
Stem Cell Transplantation ◽  
Cell Transplantation ◽  
Hematopoietic Stem Cell ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Hematopoietic Stem
Sign in / Sign up

Export Citation Format

Share Document